Arch Therapeutics’ AC5 Advanced Wound System Receives Dedicated HCPCS B****** Code from The Centers for Medicare & Medicaid Services

The new code represents a key milestone for the commercialization of AC5 Advanced Wound System in doctors’ offices and other outpatient settings

Arch Therapeutics, a marketer and developer of novel self-assembling wound care and biosurgical products, announced that the Centers for Medicare and Medicaid Services (“CMS”) established a new Level II Healthcare Common Procedure Coding System (“HCPCS”) code dedicated to the Company’s AC5 Advanced Wound System (“AC5”).

AiThority Interview : AiThority Interview with Shaun McGirr, Field CDO at Dataiku

The new HCPCS code, “A2020,” will become effective on April 1, 2023, creating a new pathway for reimbursement of AC5. The HCPCS code is expected to improve the ability of providers to charge CMS and other insurers for AC5 used in doctors’ offices, wound care clinics, hospital outpatient departments and ambulatory surgical centers.

Terrence Norchi, MD, Chief Executive Officer of Arch Therapeutics, said, “We have been eagerly anticipating the announcement of a unique HCPCS code for AC5. CMS’s decision to establish a separate HCPCS code for AC5 marks an important milestone for Arch in our ability to commercialize AC5 by facilitating access for providers and patients. Many clinicians have expressed interest in AC5 but have been hesitant to order in the absence of a dedicated HCPCS code. We believe that the A2020 code will improve access for new and recurring customers as well as enhance our ability to work directly with payors to advocate for clinically appropriate payment policies that can drive revenue growth.”

Read More Interview: AiThority Interview with Mario Ciabarra, Founder and CEO of Quantum Metric

AC5 was cleared as a device by the Food and Drug Administration (“FDA”) for the management of partial and full-thickness wounds, such as pressure sores, leg ulcers, diabetic ulcers, and surgical wounds. AC5 is a synthetic self-assembling wound care product that provides clinicians with multi-modal support and utility across all phases of wound healing. Case studies demonstrating that AC5 can lead to improved outcomes, including limb salvage, even for patients who have not responded to alternative modalities, may be found here

 Latest Interview Insights : AiThority Interview with Jessica Stafford, SVP of Consumer Solutions at Cox Automotive

 [To share your insights with us, please write to sghosh@martechseries.com]